VK2735 for Weight Management Phase 2

NCT06068946 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effectiveness of the medication VK2735 in helping adults with weight management over a 13-week period.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 176 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-08 · est. completion 2024-04

Where 20 sites · United States

What this study is testing ClinicalTrials.gov NCT06068946 ↗

Description as written by the study sponsor.

This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once weekly.

Treatments tested

VK2735 Biologic

VK2735 is a peptide GLP-1 and GIP dual agonist
Placebo Biologic

Placebo comparator

Main thing measured	Percent (relative) change from baseline to Week 13 in body weight
Sponsor	Viking Therapeutics, Inc.
Conditions studied	Weight Loss
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06068946 ↗